CIK 0001539029
CLSD Clearside Biomedical, Inc.
Insider trading from SEC Form 4. Last filing Feb 24, 2025.
In brief
Clearside Biomedical, Inc. (CLSD) has 6 SEC Form 4 filings on file from 5 insiders, the latest filed on Feb 24, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at CLSD. The newest: Clay Thorp (director) bought $14k of stock on Feb 24, 2025, filed Feb 24, 2025, scored 18 (weak). The largest of the 3 shown: Bradford T Whitmore (10% owner) bought $100k on Oct 30, 2023, scored 12 (weak).
Last 90 days
Signals
Open-market buys and sells at Clearside Biomedical, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Clay Thorp director buy | $14k 15,000 shares | +9% | - | |
| 31Weak | Ngai Hang Victor Chong Chief Medical Officer buy | $37k 36,500 shares | +57% | - | |
| 12Weak | Bradford T Whitmore owner buy | $100k 135,778 shares | +3% | - |
Transactions
Every row filed, 8 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 24, 2025 | Clay Thorp director | POpen-market purchase Common Stock | +15,000 | $0.92 | $14k | 176,141 | Feb 24, 2025 |
| Jan 8, 2025 | Ngai Hang Victor Chong Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jan 10, 2025 |
| Jan 8, 2025 | George M Lasezkay CEO | AGrant or award Employee Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jan 10, 2025 |
| Jan 8, 2025 | Charles A. Deignan Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jan 10, 2025 |
| Nov 1, 2024 | Ngai Hang Victor Chong Chief Medical Officer | POpen-market purchase Common Stock | +36,500 | $1.00 | $37k | 100,000 | Nov 4, 2024 |
| Oct 30, 2023 | Bradford T Whitmore owner | POpen-market purchase Common Stock | +600 | $0.69 | $411 | 3,915,412 | Nov 1, 2023 |
| Oct 31, 2023 | Bradford T Whitmore owner | POpen-market purchase Common Stock | +70,812 | $0.73 | $52k | 3,986,224 | Nov 1, 2023 |
| Nov 1, 2023 | Bradford T Whitmore owner | POpen-market purchase Common Stock | +64,366 | $0.74 | $48k | 4,050,590 | Nov 1, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Ngai Hang Victor ChongChief Medical Officer
- Charles A. DeignanChief Financial Officer
- George M LasezkayCEO
- Clay Thorpdirector
- Bradford T Whitmoreowner, director
Questions about CLSD
Answered from the filings on this page, as of the latest one.
Are insiders buying CLSD?
No. In the last 90 days no insider at Clearside Biomedical, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CLSD on the open market?
Clay Thorp (director) bought $14k of CLSD on Feb 24, 2025 and filed the Form 4 on Feb 24, 2025. InsiderTell scored 18 (weak).
How many insiders file Form 4 at Clearside Biomedical, Inc.?
5 people have filed a Form 4 at Clearside Biomedical, Inc., among them Ngai Hang Victor Chong (Chief Medical Officer), Charles A. Deignan (Chief Financial Officer), George M Lasezkay (CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.